TLX News: Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain - 29th Jul 2024, 9:30pm

annb0t

Top 20
Telix Pharmaceuticals Limited

MELBOURNE, Australia, July 29, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces the opening of an expanded access program (EAP) in the United States (U.S.) for TLX101-CDx (Pixclara™1, 18F-floretyrosine or 18F-FET) an investigational positron emission tomography (PET) agent for imaging progressive or recurrent glioma, following U.S. Food and Drug Administration (FDA) agreement to proceed.

Amino acid PET is i...

>>> Read more: Expanded Access Program Opens in the U.S. for TLX101-CDx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent
 
Top Bottom